Literature DB >> 11053761

The relationship between psychopathology and smoking cessation treatment response.

P Gariti1, A I Alterman, F D Mulvaney, L Epperson.   

Abstract

The study evaluated the relationship of psychopathology to treatment response of 208 smokers prescribed transdermal nicotine (8 weeks). Participants were relatively high functioning (DSM-IV axis V score) outpatients in a university-based clinic. The primary study objective was to determine whether patients with a history of either a DSM-IV axis I or II diagnosis would have poorer during treatment response (patch adherence, smoking) and lower rates of smoking cessation at post-patch follow-up (study weeks 9, 26, 52) than those without a diagnosis. While there was some indication that patients with a history of psychopathology wore the patch less frequently, psychopathology was not associated with during- and post-treatment smoking.

Entities:  

Mesh:

Year:  2000        PMID: 11053761     DOI: 10.1016/s0376-8716(00)00114-9

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  3 in total

1.  Extended Nicotine Patch Treatment Among Smokers With and Without Comorbid Psychopathology.

Authors:  Allison J Carroll; Amanda R Mathew; Frank T Leone; E Paul Wileyto; Andrew Miele; Robert A Schnoll; Brian Hitsman
Journal:  Nicotine Tob Res       Date:  2020-01-27       Impact factor: 4.244

2.  Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion.

Authors:  Carolyn M Mazure; Benjamin Toll; Sherry A McKee; Ran Wu; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

3.  Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis.

Authors:  Teresa R Franklin; Ronald Ehrman; Kevin G Lynch; Derek Harper; Nathan Sciortino; Charles P O'Brien; Anna Rose Childress
Journal:  J Womens Health (Larchmt)       Date:  2008-03       Impact factor: 2.681

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.